HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital

SARS-CoV Infection Clinical Trial

— H-Cov-Run  

Official title:

HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04384705
• Other study ID #: 2020/CHU/08
• Status: Active, not recruiting
• Start date: June 17, 2020
• Est. completion date: September 2023

Study information

• Verified date: August 2022
• Source: Centre Hospitalier Universitaire de la Réunion
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Since December 2019, the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic has spread around the world. The people most exposed to this virus remain the healthcare personnel who are on the front line in the fight against this pandemic. Due to the delayed nature of the pandemic in Reunion island and its insular geographical situation, the study of the voluntary medical personnel will allow the investigators to establish a longitudinal follow-up of the anomalies of the lipidic balance in relation to the exposure to the SARS-Cov virus. 2. During bacterial infections, the lipid profiles are profoundly modified with very significant reductions in plasma cholesterol levels, LDL-C but especially HDL-C whose concentrations are particularly low. Lipid profiles are altered during viral infections, for example, the severity of dengue is inversely correlated with total cholesterol and LDL-C but not with HDL-C levels, according to a recent meta-analysis. The hepatitis C virus circulates in serum linked to lipoproteins rich in triglycerides and HDL can facilitate its entry into cells via Scavenger receptor class B type 1 (SRB1). Likewise, it has been shown that apoA1 can bind to the dengue virus and increase its infectivity by promoting its entry into cells, also via SRB1. At the moment, nothing is known about the lipid profiles in subjects with SARS-CoV-2. The investigator hypothesize that a drop in plasma HDL-C levels and a change in their size during infection could justify future therapeutic approaches aimed at supplementing the subjects most at risk of pulmonary complications. In a model of Pseudomonas aeruginosa pneumonia in mice, investigators have shown that the injection of reconstituted HDL allowed to limit the pulmonary inflammation and the deleterious consequences of the infection. The investigator propose to study not only the lipid profiles in subjects who are infected with SARS-CoV-2 but also the polymorphisms of genes involved in the regulation of lipoprotein levels like that of Cholesterol Ester-Transfer Protein (CETP) depending on the developed forms, symptomatic or not.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 361
• Est. completion date: September 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Caregiver in Reunion island University Hospital Center

• Practicing in a care service possibly exposed to the coronavirus

• Signed Consent

Exclusion Criteria:

• Refusal to participate

• Already infected by Covid19

Related Conditions & MeSH terms

• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

Intervention

Other:
• research specific blood sample
one blood sample before the epidemic phase one blood sample during epidemic phase one blood sample after epidemic phase

Locations

Country	Name	City	State
France	Centre Hospitalier Universitaire Réunion	Saint-Denis
France	Centre Hospitalier Universitaire de la Réunion	Saint-Pierre

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de la Réunion

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of lipid profile during exposure to SARS-Cov-2	lipid profile	at the end of the study, maximum 1 year
Secondary	HDL-cholesterol size	HDL-cholesterol size	at the end of the study, maximum 1 year
Secondary	circulating plasma cytokine levels	circulating plasma cytokine levels	at the end of the study, maximum 1 year
Secondary	ACE2 gene polymorphisms	ACE2 gene polymorphisms	at the end of the study, maximum 1 year